Clinical Trial Detail

NCT ID NCT01560923
Title Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications

prostate adenocarcinoma

Therapies

Sipuleucel-T

Age Groups: adult

No variant requirements are available.